Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new screening test, funded by NIHR Oxford BRC, is being hailed the most efficient way to indicate risk of colorectal cancer.

First stage UK research, published today, shows that an advanced computer algorithm technology can successfully indicate levels of risk by analysing previous blood test results in patients’ existing medical records.

The paper, ‘Evaluation of a prediction model for colorectal cancer: retrospective analysis of 2.5 million patient records’, is published today in the journal Cancer Medicine.

Advances in algorithm technology – a mathematical analysis of data – have led to the ability to search ultra-rapidly through existing NHS records to determine whether a patient is at risk of colorectal cancer.

This has the potential to save lives through early detection as well as reducing the need for unnecessary costly and invasive tests.

The algorithm, established in Tel Aviv and shown to work on the Israeli population, has now been trialled in the very different UK population.

This radically different approach has been tested over the past two years by Oxford University and funded by the NIHR Oxford Biomedical Research Centre.

Read more (Oxford Biomedical Research Centre website)

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

AIMday in Women's Health - registration for academics now open

Events Innovation

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.